blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2382012

EP2382012 - PHARMACEUTICAL COMPOUNDS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  08.07.2022
Database last updated on 08.06.2024
FormerGrant of patent is intended
Status updated on  14.10.2021
FormerExamination is in progress
Status updated on  08.05.2021
FormerGrant of patent is intended
Status updated on  04.10.2020
FormerExamination is in progress
Status updated on  31.07.2020
FormerGrant of patent is intended
Status updated on  19.03.2020
FormerExamination is in progress
Status updated on  12.01.2018
Most recent event   Tooltip08.07.2022Application deemed to be withdrawnpublished on 10.08.2022  [2022/32]
Applicant(s)For all designated states
BIAL - Portela & CA., S.A.
Av. da Siderurgia Nacional
4745-457 S. Mamede do Coronado / PT
[2011/48]
Former [2011/44]For all designated states
Bial-Portela & CA, S.A.
À Avenida da Siderurgia Nacional
4745-457 S. Mamede do Coronado / PT
Inventor(s)01 / KISS, Laszlo, Erno
Av. da Siderurgia Nacional
4547-457 S. Mamede do Coronado / PT
02 / LEARMONTH, David Alexander
Av. da Siderurgia Nacional
4547-457 S. Mamede do Coronado / PT
03 / ROSA, Carla Patricia da Costa Pereira
Av. da Siderurgia Nacional
4547-457 S. Mamede do Coronado / PT
04 / GUSMÃO DE NORONHA, Rita
Av. da Siderurgia Nacional
4547-457 S. Mamede do Coronado / PT
05 / PALMA, Pedro Nuno Leal
Av. da Siderurgia Nacional
4547-457 S. Mamede do Coronado / PT
06 / SOARES DA SILVA, Patricio Manuel Vieira Araújo
Av. da Siderurgia Nacional
4547-457 S. Mamede do Coronado / PT
07 / BELIAEV, Alexander
Av. da Siderurgia Nacional
4547-457 S. Mamede do Coronado / PT
 [2011/44]
Representative(s)Jones, Nicholas Andrew, et al
Withers & Rogers LLP
2 London Bridge
London SE1 9RA / GB
[N/P]
Former [2011/44]Jones, Nicholas Andrew, et al
Withers & Rogers LLP
4 More London Riverside
London
SE1 2AU / GB
Application number, filing date09801307.123.12.2009
WO2009PT00080
Priority number, dateUS20080140640P24.12.2008         Original published format: US 140640 P
US20090159281P11.03.2009         Original published format: US 159281 P
US20090174712P01.05.2009         Original published format: US 174712 P
US20090221166P29.06.2009         Original published format: US 221166 P
US20090242472P15.09.2009         Original published format: US 242472 P
[2011/44]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2010074588
Date:01.07.2010
Language:EN
[2010/26]
Type: A2 Application without search report 
No.:EP2382012
Date:02.11.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 01.07.2010 takes the place of the publication of the European patent application.
[2011/44]
Search report(s)International search report - published on:EP19.05.2011
ClassificationIPC:A61P3/00, A61K31/33
[2011/44]
CPC:
C07D401/12 (EP,CN,US); C07D413/06 (EP,CN,KR,US); C07D401/14 (EP,CN,US);
A61K31/4178 (KR); A61P1/00 (EP); A61P1/04 (EP);
A61P1/08 (EP); A61P1/14 (EP); A61P1/16 (EP);
A61P11/00 (EP); A61P11/06 (EP); A61P19/02 (EP);
A61P19/10 (EP); A61P21/00 (EP); A61P21/04 (EP);
A61P25/00 (EP); A61P25/04 (EP); A61P25/08 (EP);
A61P25/14 (EP); A61P25/16 (EP); A61P25/18 (EP);
A61P25/20 (EP); A61P25/22 (EP); A61P25/24 (EP);
A61P25/28 (EP); A61P25/30 (EP); A61P25/32 (EP);
A61P25/34 (EP); A61P25/36 (EP); A61P27/02 (EP);
A61P27/06 (EP); A61P29/00 (EP); A61P3/00 (EP);
A61P3/04 (EP); A61P35/00 (EP); A61P43/00 (EP);
A61P9/00 (EP); A61P9/10 (EP); A61P9/12 (EP);
C07D209/08 (CN); C07D231/12 (EP,CN,US); C07D233/56 (EP,CN,KR,US);
C07D233/60 (EP,CN,US); C07D249/08 (CN); C07D249/10 (EP,CN,US);
C07D249/18 (EP,CN,US); C07D401/04 (EP,CN,US); C07D401/06 (CN);
C07D401/10 (EP,CN,US); C07D405/10 (EP,CN,US); C07D405/12 (EP,CN,US);
C07D409/04 (EP,CN,US); C07D413/10 (EP,CN,KR,US); C07D413/14 (EP,CN,US);
C07D417/14 (EP,CN,US); C07D453/02 (CN); C07D471/04 (CN);
C07D491/113 (CN) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2011/50]
Extension statesAL04.11.2011
BA04.11.2011
RS04.11.2011
TitleGerman:PHARMAZEUTISCHE VERBINDUNGEN[2011/44]
English:PHARMACEUTICAL COMPOUNDS[2011/44]
French:COMPOSÉS PHARMACEUTIQUES[2011/44]
Entry into regional phase22.07.2011National basic fee paid 
Examination procedure04.11.2011Examination requested  [2011/50]
03.04.2012Amendment by applicant (claims and/or description)
16.01.2018Despatch of a communication from the examining division (Time limit: M04)
14.05.2018Reply to a communication from the examining division
04.04.2019Despatch of a communication from the examining division (Time limit: M06)
03.01.2020Reply to a communication from the examining division
20.03.2020Communication of intention to grant the patent
30.07.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
05.10.2020Communication of intention to grant the patent
07.05.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
15.10.2021Communication of intention to grant the patent
26.02.2022Application deemed to be withdrawn, date of legal effect  [2022/32]
22.03.2022Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2022/32]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.01.2018
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
07.05.2021Request for further processing filed
07.05.2021Full payment received (date of receipt of payment)
Request granted
14.09.2021Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
03.01.2020Request for further processing filed
03.01.2020Full payment received (date of receipt of payment)
Request granted
16.01.2020Decision despatched
Fees paidRenewal fee
22.12.2011Renewal fee patent year 03
20.12.2012Renewal fee patent year 04
17.12.2013Renewal fee patent year 05
19.12.2014Renewal fee patent year 06
09.12.2015Renewal fee patent year 07
09.12.2016Renewal fee patent year 08
13.12.2017Renewal fee patent year 09
10.12.2018Renewal fee patent year 10
10.12.2019Renewal fee patent year 11
10.12.2020Renewal fee patent year 12
10.12.2021Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XI]US4233059  (KRUEGER HANS-RUDOLF, et al) [X] 1-20,28-36,56-59,61-68 * claim -; compound - * [I] 1-20,28-36,56-59,61-68;
 [XI]JPH0559017  (UBE INDUSTRIES) [X] 1-20,28-36,56-59,61-68 * claim -; compound - * [I] 1-20,28-36,56-59,61-68;
 [XI]JPH0649041  (MITSUBISHI PETROCHEMICAL CO) [X] 1-20,28-36,56-59,61-68 * abstract * [I] 1-20,28-36,56-59,61-68;
 [XI]US5883110  (TANG PENG CHO [US], et al) [X] 1-68 * abstract * [I] 1-68;
 [XI]US6262093  (CAMDEN JAMES BERGER [US]) [X] 1-68 * abstract * [I] 1-68;
 [XI]WO0170671  (DU PONT [US], et al) [X] 1-38,40-52,56-68 * example -; claim -; compound - * [I] 1-38,40-52,56-68;
 [XI]JP2001302640  (TOKUYAMA CORP) [X] 1-38,40-52,56-68 * example -; claim -; compound - * [I] 1-38,40-52,56-68;
 [XI]WO0226716  (PROCTER & GAMBLE [US]) [X] 1-68 * example -; claim -; compound - * [I] 1-68;
 [XI]WO0230886  (MATTHEWS BARRY R [AU], et al) [X] 1-68 * example -; claim -; compound - * [I] 1-68;
 [XI]WO02072576  (PFIZER PROD INC [US], et al) [X] 1-20,28-36,56-59,61-68 * abstract * [I] 1-20,28-36,56-59,61-68;
 [XI]WO02088113  (PROCTER & GAMBLE [US]) [X] 1-20,28-36,56-59,61-68 * example -; claim -; compound - * [I] 1-20,28-36,56-59,61-68;
 [XI]WO02088108  (PROCTER & GAMBLE [US]) [X] 1-20,28-36,56-59,61-68 * example -; claim -; compound - * [I] 1-20,28-36,56-59,61-68;
 [XI]US2003045559  (PILLARISETTI SIVARAM [US], et al) [X] 1-20,28-36,56-59,61-68 * example -; claim -; compound - * [I] 1-20,28-36,56-59,61-68;
 [XI]WO03051842  (NOVO NORDISK AS [DK]) [X] 1-20,28-36,56-59,61-68 * example -; claim -; compound - * [I] 1-20,28-36,56-59,61-68;
 [XI]JP2003327532  (TAKEDA CHEMICAL INDUSTRIES LTD) [X] 1-20,28-36,56-59,61-68 * claim -; compound - * [I] 1-20,28-36,56-59,61-68;
 [X]WO2004035550  (AVENTIS PHARMA GMBH [DE]) [X] 1-20,28-37,39,53,59 * figure -; example -; claim -; compound - *;
 [XI]WO2004046120  (VERTEX PHARMA [US], et al) [X] 1-20,28-36,56-59,61-68 * abstract * [I] 1-20,28-36,56-59,61-68;
 [XI]WO2005014576  (TAKEDA PHARMACEUTICAL [JP], et al) [X] 1-38,40-52,56-68 * example -; claim -; compound - * [I] 1-38,40-52,56-68;
 [XI]WO2006032852  (BIOLIPOX AB [SE], et al) [X] 1-20,28-36,56-59,61-68 * example -; claim -; compound - * [I] 1-20,28-36,56-59,61-68;
 [XI]WO2007030680  (RIGEL PHARMACEUTICALS INC [US], et al) [X] 1-20,28-36,56-59,61-68 * example -; claim -; compound - * [I] 1-20,28-36,56-59,61-68;
 [XI]WO2007045393  (SANOFI AVENTIS DEUTSCHLAND [DE], et al) [X] 1-68 * figure -; example -; claim -; table -; compound - * [I] 1-68;
 [XI]WO2007051981  (BIOLIPOX AB [SE], et al) [X] 1-20,28-36,56-59,61-68 * example -; claim -; compound - * [I] 1-20,28-36,56-59,61-68;
 [XI]WO2008064255  (PLEXXIKON INC [US], et al) [X] 1-20,28-36,56-59,61-68 * example -; claim -; compound - * [I] 1-20,28-36,56-59,61-68;
 [XI]  - OPACIC, NINOSLAV ET AL, "The Novel L- and D-Amino Acid Derivatives of Hydroxyurea and Hydantoins: Synthesis, X-ray Crystal Structure Study, and Cytostatic and Antiviral Activity Evaluations", JOURNAL OF MEDICINAL CHEMISTRY , 48(2), 475-482 CODEN: JMCMAR; ISSN: 0022-2623, (2005), XP002610629 [X] 1-20,28-37,39,53,59,61-68 * page 476 - page 478; table 1; compounds 4a-o * [I] 1-20,28-37,39,53,59,61-68

DOI:   http://dx.doi.org/10.1021/JM040869I
 [X]  - DZIMBEG, G. ET AL, "The novel primaquine derivatives of N-alkyl, cycloalkyl or aryl urea: Synthesis, cytostatic and antiviral activity evaluations", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , 43(6), 1180-1187 CODEN: EJMCA5; ISSN: 0223-5234, (20070915), vol. 43, XP002610630 [X] 1-20,28-37,39,53,59 * page 1181, column L; compound 2 *

DOI:   http://dx.doi.org/10.1016/J.EJMECH.2007.09.001
 [X]  - OPACIC, N. ET AL, "Synthesis and X-ray crystal structure study of the hydroxyurea and hydantoin derivatives of L-valine", JOURNAL OF PEPTIDE RESEARCH , 66(2), 85-93 CODEN: JPERFA; ISSN: 1397-002X, (2005), XP002610631 [X] 1-20,28-37,39,53,59 * page 88; compound 4 *

DOI:   http://dx.doi.org/10.1111/J.1399-3011.2005.00276.X
 [X]  - RAJIC, ZRINKA ET AL, "Hydantoin derivatives of L- and D-amino acids: synthesis and evaluation of their antiviral and antitumor activity", MOLECULES , 11(11), 837-848 CODEN: MOLEFW; ISSN: 1420-3049 URL: HTTP://WWW.MDPI.ORG/MOLECULES/PAPERS/11110837.PDF, (2006), XP002610632 [X] 1-20,28-37,39,53,59 * page 839; compound 4 *
    [ ] - KITAMURA, SHUJI ET AL, "Preparation of isoquinoline derivatives as c-Jun N-terminal kinase (JNK) inhibitors", CHEMICAL ABSTRACTS, (20050217), vol. 2005, Database accession no. 141054 [ ] * compound - *
 [XI]  - ASANO, YASUTOMI ET AL, "Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (2)", BIOORGANIC & MEDICINAL CHEMISTRY , 16(8), 4699-4714 CODEN: BMECEP; ISSN: 0968-0896, (20081215), XP002629241 [X] 1-38,40-52,56-68 * page 4699 - page 4704; compound 14e * [I] 1-38,40-52,56-68

DOI:   http://dx.doi.org/10.1016/J.BMC.2008.02.028
 [XI]  - LAHM, GEORGE P. ET AL, "Preparation of insecticidal anthranilamides", CHEMICAL ABSTRACTS, (20010927), vol. 2001, Database accession no. 713292 [X] 1-38,40-52,56-68 * compound - * [I] 1-38,40-52,56-68
 [XI]  - HIRANO, NAOKI ET AL, "Phosgene-free preparation of carbonyldiazole compounds from silylazoles", CHEMICAL ABSTRACTS, (20011031), vol. 2001, Database accession no. 791907 [X] 1-38,40-52,56-68 * compound - * [I] 1-38,40-52,56-68
 [XI]  - YANO, TOSHIHIKO ET AL, "Preparation of tribromoimidazoles as insecticides for cockroaches", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (19911101), Database accession no. 1992:123311, URL: STN, XP002629248 [X] 1-38,40-52,56-68 * abstract * [I] 1-38,40-52,56-68
 [XI]  - TAHA, MUTASEM O. ET AL, "Combining Ligand-Based Pharmacophore Modeling, Quantitative Structure-Activity Relationship Analysis and in Silico Screening for the Discovery of New Potent Hormone Sensitive Lipase Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY , 51(20), 6478-6494 CODEN: JMCMAR; ISSN: 0022-2623, (20081023), XP002629243 [X] 1-20,28-36,56-59,61-68 * abstract * [I] 1-20,28-36,56-59,61-68

DOI:   http://dx.doi.org/10.1021/jm800718k
 [XI]  - SAGRADA, ANGELO ET AL, "Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (20111101), Database accession no. 1992:34274, URL: STN, XP002629244 [X] 1-68 * abstract * [I] 1-68
ExaminationUS3868458
by applicantUS7208504
 FR2915198
 FR2915199
 FR2915197
 WO2009117444
    - PACHER ET AL., PHARMACOL. REV., (2006), vol. 58, pages 389 - 462
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.